

Musculoskeletal Disorders in Elderly

Reza S. Roghani
MD, Ph.D




Musculoskeletal Diseases and Demographic Characteristics

- **Low Back and Neck Pain**
- **Spinal Deformity**
- **Arthritis and Related Conditions**
- **Osteoporosis and Bone Health**
- **Injuries – Traumatic, Workplace, Sports, Military**
- **Children and Adolescents**
- **Tumors of Bones and Joints, Muscles and Tissues**
- **Rare Bone Diseases**
- **Neuromuscular Disorders**
- **Diseases of the Muscles**
- **Aging**
- **Sex and Gender**


Prevalence of Musculoskeletal Diseases

- **1 in 2** (126.6 million) adults are affected, twice the rate of chronic heart and lung conditions




- Disproportionately affect older persons, accounting for >50% of all chronic conditions in people older than 50 years
- Age 65 and older population to nearly double in next 25 years

In 2040, persons age 65 and older will constitute 21% of US population, equal to the share who are 18 and under.




Health Care Visits for Musculoskeletal Diseases

- ❖ **18%** of all health care visits in 2010/2011 had a musculoskeletal condition diagnosis listed
- ❖ **29%** of hospital discharges
- ❖ **16%** of physician visits
- ❖ **14%** of outpatient visits
- ❖ **29%** of emergency department visits




Chronic Pain of Musculoskeletal Diseases

- ❖ **1 in 4** persons over age of 18 report chronic joint pain in at least one joint
- ❖ **Knee** is the most frequent site (17%)
- ❖ **Shoulder** is 2nd most frequent site (8%)
- ❖ **Hip** is 3rd most frequent site (6%)
- ❖ **40%** = percentage of persons over age 65 with chronic joint pain




Limitations due to Musculoskeletal Diseases

- ❖ **6%** of population reports limitations carrying out common activities of daily living (eating, dressing, bathing) due to musculoskeletal diseases
- ❖ **14%** ages 65-75 report limitations due to musculoskeletal condition
- ❖ **23%** age 75 and older
- ❖ **Twice the rate** of circulatory (heart conditions), the second highest cause of limitations



Limitations due to Specific MSK Diseases

- ❖ **5%-6%** of population over age 18 report limitations carrying out common activities of daily living are **due to back or neck problems**
- ❖ **14%** age 75 and older have limitations due to **arthritis**
- ❖ **For all musculoskeletal** diseases, the rate of limitations increases sharply as population ages



Osteoarthritis of The Knee

I. Overview

- ❖ **Definition**
- ❖ **Risk Factors**


II. Clinical Approach to Knee Pain

III. Differential Diagnosis

IV. Diagnosis of Knee OA

V. Management

- ❖ **Lifestyle**
- ❖ **Medical**
- ❖ **Surgical**



Overview: Definition

Arthritis vs. Arthrosis


Gradual loss of articular cartilage in the knee joint

- **3 articulations:**
 - 1) **Lateral condyles of the femur and tibia**
 - 2) **Medial condyles of the femur and tibia**
 - 3) **Patellofemoral joint**


Damage caused by a complex interplay of joint integrity, biochemical processes, genetics, and mechanical forces



Anatomy of The Knee



Anatomy of The Knee



Overview: Risk Factors

- **Age ³**
- **Female**
- **Obesity**
- **Previous knee injury**
- **Lower extremity malalignment**
- **Repetitive knee bending**
- **High impact activities**
- **Muscle weakness ⁴**



Clinical Approach to Knee Pain

“Hey Doc, my knee’s been hurting!”

History

- **SOCRATES pain questions**
- **Inflammatory sx e.g. fever, hot joint**
- **History of trauma or surgery**
- **Instability**
- **Functional loss**
- **Prior treatment**




Clinical Approach to Knee Pain

Physical Exam


- **Vitals, BMI**
- **Palpation: isolate tenderness, effusion, crepitus**
- **ROM: measure degree of flexion**
- **Stability: ligaments, menisci**
- **Alignment: genu varus or valgus**
- **Function: gait, duck waddle**



Clinical Approach to Knee Pain



Valgus Test (MCL)



Varus Test (LCL)



Lachman Test (ACL)



**McMurray Maneuver
(menisci)**



**Duck Waddle
(stability)**

Differential Diagnosis of Knee Pain

Medial Pain

- OA
- MCL
- Meniscus
- Bursitis

Diffuse Pain

- OA
- Infectious arthritis
- Gout, pseudogout
- RA

Lateral Pain

- OA
- LCL
- Meniscus
- Iliotibial band syndrome



Anterior Pain

- OA
- Patellofemoral syndrome
- Prepatellar bursitis
- Quadriceps mechanism



Para- Clinic

- **CBC, ESR, RF**
- **Arthrocentesis**
- **X-rays (3 views)**
 - **Weight-bearing AP**
 - **Lateral**
 - **Tangential Patellar (Sunrise)**
- **MRI**



Diagnosis of Knee OA

Classic Clinical Criteria

- established by ACR, 1981
- sensitivity 95%, specificity 69%

➤ knee pain plus at least 3 of 6 characteristics:


- > 50 yo
- Morning stiffness < 30 min
- Crepitus
- Bony tenderness
- Bony enlargement
- No palpable warmth ⁵





Diagnosis of Knee OA

Classification Tree

- **Clinical symptoms**
 - **Synovial fluid**
 1. **WBC < 2000/mm³**
 2. **Clear color**
 3. **High Viscosity**
 - **X-rays**
 1. **Osteophytes**
 2. **Loss of joint space**
 3. **Subchondral sclerosis**
 4. **Subchondral cysts**
- Confirmed by arthroscopy (gold standard) ⁶




Diagnosis of Knee OA



Management: Lifestyle

- **Weight loss**
 - **Nutrition referral**
- **Exercise Program**
 - **PT referral**
 - **Quadriceps strengthening**
 - **ROM exercises**
 - **Low impact activities e.g. swimming, biking ⁷**
- **Ambulatory assist devices**
 - **Cane**
 - **Walker**
- **Insoles**
- **Unloader knee braces**




Management: Lifestyle

Varus (bowlegged) vs Valgus (knock-kneed)



G2 Unloader Brace




Management: Medical

- **Glucosamine/Chondroitin**
- **Acetaminophen**
- **NSAIDs**
- **Cox-2 inhibitors**
- **Opioids**
- **Intraarticular injections**
 - **Glucocorticoids**
 - **Hyaluronans**



Management: Medical

- **Glucosamine/Chondroitin**
 - **1500 mg/1200 mg daily (\$40-50/month)**
 - **Glucosamine: building block for glycosaminoglycans**
 - **Chondroitin: glycosaminoglycan in articular cartilage**
 - **For mild OA, not better than placebo**
 - **For moderate-severe OA, combination showed benefit ⁸**
 - **Patient satisfaction**




Management: Medical

- **Acetaminophen**

- **Indication: mild-moderate pain**
- **1000 mg Q6h PRN**
- **Better than placebo but less efficacious than NSAIDs⁹**
- **Caution in advanced hepatic disease**

- **NSAIDs**

- **Indication: moderate-severe pain, failed acetaminophen**
- **GI/renal/hepatic toxicity, fluid retention**
- **If risk of GIB, use anti-ulcer agents concurrently**
- **Agents have highly variable efficacy and toxicity**



Management: Medical


• NSAIDs

10

Dose and Cost of Nonsteroidal Antiinflammatory Drugs					
Agent	Brand name(s)	Dosing	Daily dose	Specific benefits	Cost
Salicylates					
Aspirin		BID-QID	500-4000 mg	Titrate dose by serum levels	\$
Choline magnesium trisalicylate	Trilisate	BID-QID	975-3600 mg	Decreased GI toxicity, titrate dose by serum levels	\$\$\$\$
Salsalate	Disalcid, Salflex, Monogesic	BID-QID	975-3600 mg	Decreased GI toxicity, titrate dose by serum levels	\$\$\$\$
Short half-life NSAID					
Fenoprofen calcium	Nalfon	TID-QID	900-2400 mg		\$\$
Ibuprofen	Motrin, Advil, Midol, Nuprin	TID-QID	600-3600 mg	Generally fewer side effects	\$
Indomethacin	Indocin	TID-QID	75-200 mg	Excellent efficacy if tolerated	\$\$
Ketoprofen	Orudis	TID-QID	75-300 mg	Dialyzable	\$
Meclofenamate sodium	Meclomen	TID-QID	150-400 mg		\$\$
Tolmetin	Tolectin	TID-QID	600-2000 mg		\$
Intermediate half-life NSAID					
Diclofenac	Cataflam, Voltaren	BID-QID	100-200 mg		\$
Etodolac	Lodine	BID-QID	400-1200 mg		\$\$\$\$
Flurbiprofen	Ansaid	BID-QID	100-300 mg		\$\$\$\$
Naproxen	Naproxyn, Napron X	BID-TID	500-1500 mg		\$
Naproxen-sodium	Anaprox, Aleve	BID-TID	550-1650 mg		\$
Sulindac	Clinoril	BID	150-400 mg	Decreased renal prostaglandin effect	\$\$
Diflunisal	Dolobid	BID	500-1000 mg	Most uricosuric NSAID	\$\$\$\$
Long half-life NSAID					
Nabumetone	Relafen	QD-BID	1000-2000 mg	Decreased GI side effects	\$\$\$
Oxaprozin	Daypro	QD-BID	600-1800 mg		\$
Piroxicam	Feldene	QD	10-20 mg		\$

Management: Medical

- **Cox-2 inhibitors**
 - **Indication: mod-severe pain, failed NSAID, risk of GIB**
 - **OA pain relief similar to NSAIDs**
 - **Fewer GI events e.g. symptomatic ulcers, GIB**
 - **Celecoxib 200 mg daily**
 - **GI/renal toxicity, fluid retention**
 - **Increased risk of CV events?**
 - **APC Trial: 700 pts each assigned to placebo, 200 BID, 400 BID**
 - **Increased risk at higher doses ¹¹**
 - **CLASS Trial: 8,000 pts compared Celecoxib vs Ibuprofen**
 - **Similar risk to Ibuprofen ¹²**



Management: Medical

- **Opioid Analgesics**

- **Indication:**

- **Moderate-severe pain**
 - **Acute exacerbations**
 - **NSAIDs/Cox-2 inhibitors failed or contraindicated**

- **Oxycodone synergistic w/ NSAIDs ¹³**

- **Tramadol/acetaminophen vs codeine/acetaminophen**

- **Similar pain relief ¹⁴**

- **Avoid long-term use**

- **Caution in elderly**

- **Confusion, sedation, constipation**




Management: Medical

Intraarticular Injections

- **Glucocorticoids**

- **Indication: pain persists despite oral analgesics**
- **40 mg/mL triamcinolone (kenalog-40)**
- **Solution: 5 mL (lidocaine 4 mL + kenalog 1 mL)**
- **Limit to Q3months, up to 2 yrs**
- **Effective for short-term pain relief < 12 wks**
- **Acute flare w/in 48 hrs post-injection ¹⁵**



Management: Medical

Intraarticular Injections

- **Hyaluronans (e.g. Synvisc)**
 - **Indication: pain persists despite other agents**
 - **Synthetic joint fluid**
 - **Pain relief similar to steroid injections**
 - **2 mL injection Qwk x 3, \$560-760/series**
 - **Medicare reimburses 80%, Medi-cal \$455.90**
 - **60-70% patients respond, relief up to 6 months**
 - **Patient satisfaction ^{16, 17}**




Management: Medical

Intraarticular Injections

- **Technique**

- **22 gauge 1.5 inch needle**
- **Approach accuracy:**
 - **Lateral mid-patellar 93%¹⁸**
- **Patient supine**
- **Leg straight**
- **Manipulate patella**
- **Angle needle slightly posteriorly**
- **Inject after drop in resistance or fluid aspirated**



Management: Algorithm

Lifestyle Modifications

Acetaminophen PRN

NSAIDs PRN


Celecoxib

Steroid Injections

Opioids PRN

Hyaluronan Injections

Surgical Referral




Management: Surgical

When to Refer

- **Knee pain or functional status has failed to improve with non-operative management**

Types of Procedures

- **Arthroscopic Irrigation**
- **Arthroscopic Debridement**
- **High Tibial Osteotomy**
- **Partial Knee Arthroplasty**
- **Total Knee Arthroplasty**



Management: Surgical

High Tibial Osteotomy

- **Indication:**
 - **Unicompartmental arthritis**
 - **Genu varus or valgus**
- **Realign mechanical axis**
- **Age < 60yo**
- **< 15 degrees deformity¹⁹**



Management: Surgical

Partial Knee Arthroplasty

- **Indication:**
 - **Unicompartmental arthritis**
- **Ligaments spared**
- **Increased ROM**
- **Faster recovery**
- **Prosthesis 10-yr survival: 84%²⁰**



Management: Surgical

Total Knee Arthroplasty

- **Indication:**
 - Diffuse arthritis
 - Severe pain
 - Functional impairment
- Pain relief > functional gain
- ACL sacrificed
- PCL also may be sacrificed
- Prosthesis 10-yr survival: 90% ²¹

